文献速递糖尿病

单次采血简化症状前1型糖尿病进展预测

Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.
PubMed 文献 · Diabetologia · 2021-08-02

研究基于TrialNet数据开发单次OGTT时间点(0、30、60、90或120分钟)预测模型,并在多个高危人群及普通儿童人群中验证。Cox模型结合血糖、C肽、性别、年龄、BMI、HbA1c及胰岛素瘤抗原-2自身抗体状态,M60、M90、M120的AUC分别为0.760、0.761、0.745,与需五次采血的黄金标准风险评分AUC 0.760无显著差异。M120操作简便且跨人群有效,可降低风险分层的成本与复杂性。

要点

  • 单次OGTT采血模型可准确预测1型糖尿病从1/2期进展至3期。
  • M60、M90、M120的AUC与需五次采血的黄金标准风险评分无显著差异。
  • M120在TEDDY中AUC为0.865,在Fr1da中显著优于M60。

核心结论

  • 基于单次OGTT采血的预测模型可准确预测症状前1型糖尿病从1期或2期进展至3期。

研究设计与样本

  • 使用TrialNet数据开发预测模型,并在TrialNet、DPT-1、TEDDY及Fr1da普通儿童人群中验证。

主要发现

  • Cox比例风险模型结合血糖、C肽、性别、年龄、BMI、HbA1c及胰岛素瘤抗原-2自身抗体状态可预测所有人群的疾病进展。
  • 在TrialNet中,M60、M90、M120的AUC分别为0.760、0.761、0.745,与黄金标准DPTRS的AUC 0.760无显著差异。
  • 在TEDDY中仅进行120分钟采血,M120的AUC为0.865。
  • 在Fr1da中,M120的AUC 0.742显著高于M60的AUC 0.615。

关键数值与推荐

  • M60、M90、M120分别基于OGTT 60、90、120分钟单次采血。
  • 黄金标准DPTRS需五次OGTT采血,其AUC为0.760。

临床怎么用

  • M120操作简便、跨高危人群有效且需120分钟采血以分期1型糖尿病,可应用于降低风险分层的成本与复杂性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Accurate prediction of disease progression in individuals with pre-symptomatic type 1 diabetes has potential to prevent ketoacidosis and accelerate development of disease-modifying therapies. Current tools for predicting risk require multiple blood samples taken during an OGTT. Our aim was to develop and validate a simpler tool based on a single blood draw. METHODS: Models to predict disease progression using a single OGTT time point (0, 30, 60, 90 or 120 min) were developed using TrialNet data collected from relatives with type 1 diabetes and validated in independent populations at high genetic risk of type 1 diabetes (TrialNet, Diabetes Prevention Trial-Type 1, The Environmental Determinants of Diabetes in the Young [1]) and in a general population of Bavarian children who participated in Fr1da. RESULTS: Cox proportional hazards models combining plasma glucose, C-peptide, sex, age, BMI, HbA1c and insulinoma antigen-2 autoantibody status predicted disease progression in all populations. In TrialNet, the AUC for receiver operating characteristic curves for models named M60, M90 and M120, based on sampling at 60, 90 and 120 min, was 0.760, 0.761 and 0.745, respectively. These were not significantly different from the AUC of 0.760 for the gold standard Diabetes Prevention Trial Risk Score, which requires five OGTT blood samples. In TEDDY, where only 120 min blood sampling had been performed, the M120 AUC was 0.865. In Fr1da, the M120 AUC of 0.742 was significantly greater than the M60 AUC of 0.615. CONCLUSIONS/INTERPRETATION: Prediction models based on a single OGTT blood draw accurately predict disease progression from stage 1 or 2 to stage 3 type 1 diabetes. The operational simplicity of M120, its validity across different at-risk populations and the requirement for 120 min sampling to stage type 1 diabetes suggest M120 could be readily applied to decrease the cost and complexity of risk stratification.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bediaga NG, Li-Wai-Suen CSN, Haller MJ, et al. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia. 2021. PMID: 34338806. doi:10.1007/s00125-021-05523-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。